Pharmacokinetics and acute toxicology of intraventricular 131I-monoclonal antibody targeting disialoganglioside in non-human primates Journal Article


Authors: Kramer, K.; Cheung, N. K. V.; Humm, J.; DiResta, G.; Arbit, E.; Larson, S.; Finn, R.; Rosenblum, M.; Nguyen, H.; Gonzalez, G.; Liu, C.; Yang, Y. F.; Mendelsohn, M. E.; Gillio, A. P.
Article Title: Pharmacokinetics and acute toxicology of intraventricular 131I-monoclonal antibody targeting disialoganglioside in non-human primates
Abstract: Tumors metastatic to the leptomeninges are often incurable despite current aggressive treatment modalities. Regional therapy by intrathecal administration of monoclonal antibodies (MoAbs) can maximize their concentration to tumor sites while reducing systemic toxicities. Anti-G(D2) antibody 3F8 has successfully targeted human neuroectoderm derived tumors. Disialoganglioside G(D2) expression in the central nervous system is identical between humans and cynomolgus monkeys. We studied the pharmacokinetics and the acute and subacute toxicities of intraventricular 131I-3F8 in 8 cynomolgus monkeys. Four animals were purposely immunized with intravenous 3F8 administered 2-4 weeks prior to injections. All animals remained clinically stable. Toxicities included weight loss, fever and CSF leukocytosis. One animal developed a left-sided hemiparesis following his seventh injection, presumably due to a local drug accumulation in the setting of an intermittently patent catheter. The estimated radiation dose to the CSF was 19-48 Gy in the immunized monkeys and 19-82 Gy in the nonimmunized monkeys, and to blood was 0.11-0.98 Gy and 0.29-2.03 Gy, respectively. Histopathology revealed chronic reactive changes adjacent to the region of catheter placement and a focal vasculitis in 2 animals. Peripheral blood counts and bone marrow examinations remained normal. Because of the blood-brain barrier, CSF monkey-anti-mouse antibody titers were less than 10 per cent of those in the serum. In contrast to the CSF radioactivity clearance which was similar in all animals, blood clearance was substantially accelerated in 3F8-immunized animals versus controls. Correspondingly, the CSF to blood dose ratio was improved 1.3 to 6.6 fold (mean 3.5). We conclude that intraventricular administration of 131I-3F8 in primates is tolerable. It can deliver very high doses of radiation to the CSF space with minimal toxicity to blood and bone marrow. Serum anti-mouse antibody accelerates the clearance of 131I-3F8 in blood and may improve the therapeutic index.
Keywords: controlled study; protein expression; constipation; histopathology; diarrhea; nonhuman; drug targeting; radiation dose; anorexia; linear models; animals; animal tissue; metastasis; stomatitis; vomiting; animal experiment; weight reduction; radiation dosage; monoclonal antibody; fever; antibodies, monoclonal; iodine 131; drug accumulation; iodine radioisotopes; brain; reference values; blood brain barrier; drug clearance; blood cell count; drug blood level; radioimmunotherapy; monkey; lethargy; leukocytosis; ataxia; hemiparesis; catheters, indwelling; bone marrow examination; antibody titer; immunization; gangliosides; ganglioside; macaca fascicularis; drug cerebrospinal fluid level; injections, intraventricular; intracerebroventricular drug administration; meningocele; male; article; cns malignancies; g(d2)
Journal Title: Journal of Neuro-Oncology
Volume: 35
Issue: 2
ISSN: 0167-594X
Publisher: Springer  
Date Published: 1997-11-01
Start Page: 101
End Page: 111
Language: English
DOI: 10.1023/a:1005822524905
PUBMED: 9266446
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 17 March 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hai T Nguyen
    13 Nguyen
  2. Nai-Kong Cheung
    648 Cheung
  3. Kim Kramer
    236 Kramer
  4. Ronald D Finn
    279 Finn
  5. Marc Rosenblum
    424 Rosenblum
  6. John Laurence Humm
    433 Humm
  7. Steven M Larson
    958 Larson
  8. Ehud   Arbit
    66 Arbit
  9. Alfred P. Gillio
    89 Gillio